Screener
Medifast MED EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Medifast in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Medifast’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:51 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029898
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Income (loss) before provision for income taxes | (1,941) | 526 |
| Provision for income taxes | 181 | 1,298 |
| Net loss | $(2,122) | $(772) |
| Loss per share - basic | $(0.19) | $(0.07) |
| Loss per share - diluted | $(0.19) | $(0.07) |
| Weighted average shares outstanding | ||
| Basic | 11,006 | 10,948 |
| Diluted | 11,006 | 10,948 |
Item 1. – Financial Statements
FAQ
- What is Medifast's EPS (diluted)?
- Medifast (MED) reported EPS (diluted) of -$0.19 in Q1 2026.
- How has Medifast's EPS (diluted) changed year-over-year?
- Medifast's EPS (diluted) decreased by 171.4% year-over-year, from -$0.07 to -$0.19.
- What is the long-term trend for Medifast's EPS (diluted)?
- Over 4 years (2021 to 2025), Medifast's EPS (diluted) has grown at a -40.8% compound annual growth rate (CAGR), from $13.89 to -$1.71.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Medifast's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude